-5%
Mitaprex is indicated for the treatment of the major depressive disorder (MDD).
- Mirtazapine enhances central noradrenergic and serotonergic activity by antagonizing central presynaptic α2-adrenergic receptors.
- Acts as an antagonist at 5-HT2 and 5-HT3 receptors, reducing related side effects.
- Potent antagonist of histamine (H1) receptors, explaining its sedative effects.
- Moderate antagonist at peripheral α1-adrenergic and muscarinic receptors, contributing to orthostatic hypotension and mild anticholinergic side effects.
- Rapid and well-absorbed, with peak plasma levels in ~2 hours.
- Protein Binding: ~85%.
- Elimination Half-Life: 20-40 hours (longer in females than males).
- Extensive biotransformation via demethylation, oxidation, and conjugation.
- Excretion: Through urine and feces within four days.